Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral ...

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13 th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu ...

AlphaQuest LLC reduced its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 79.8% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Last May, the Food and Drug Administration (FDA) approved the company's second product, a vaccine for respiratory syncytial ...

the company’s PIV5-based intranasal vaccine candidate, at the 13 th International RSV Symposium, occurring March 12-15 in Iguazu, Brazil. The data to be presented includes analyses of the ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

The Company has recently suggested that its revolutionary broad-spectrum antiviral drug NV-387 could have strong potential for the treatment of measles. NV-387 was found to cure a lethal RSV infection ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...